抗IL-2Rα链单抗及AK细胞治疗对肝癌细胞致瘤性的影响  

INFLUENCE OF THE ANTI-INTERLEUKIN-2 RECEPTOR α MONOCLONAL ANTIBODY AND ACTIVATED KILLER CELLS THERAPY ON TUMORIGENICITY OF HEPATOCELLULAR CARCINOMA CELLS

作　　者：孙倍成[1] 刘根寿[2] 王学浩[1] 刘庆宏[3] 

机构地区：[1]南京医科大学一附院肝胆外科,210029 [2]苏州医学院附二院普外科 [3]扬州大学医学院附属医院肿瘤外科

出　　处：《肝胆外科杂志》1999年第4期310-311,共2页Journal of Hepatobiliary Surgery

摘　　要：为研究 Ｉ Ｌ－ ２ Ｒα链单抗（ａ Ｉ Ｌ－ ２ Ｒα Ｍ Ａｂ）及肿瘤活化的杀伤细胞（ Ａ Ｋ 细胞）治疗对肝癌细胞致瘤性的影响，将近交系 Ｂａｌｂ／ｃ 小鼠随机分成５ 组，每组８ 只，分别给予 Ｈａｎｋｓ 液， Ｉ Ｌ－ ２，ａ Ｉ Ｌ－ ２ Ｒα Ｍ Ａｂ 及 Ａ Ｋ 细胞治疗，于治疗后第８ 天将 Ｈ２２肝癌细胞接种于 Ｂａｌｂ／ｃ 小鼠皮下，以观察肿瘤结节的发生率，肿瘤的潜伏期及肿瘤结节的体积和重量。结果发现 Ｉ Ｌ－ ２＋ Ａ Ｋ＋ ａ Ｉ Ｌ－２ Ｒα Ｍ Ａｂ 组肿瘤发生率较其它各组有显著差别（ Ｐ＜ ０．０５），肿瘤潜伏期延长，肿瘤结节的生长受到明显抑制，肿瘤重量与其它各组相比均有非常显著差异（ Ｐ＜ ０．０１）。该研究结果表明将 Ｉ Ｌ－ ２， Ａ Ｋ 及ａ Ｉ Ｌ－ ２ Ｒα Ｍ Ａｂ 联合应用可使肝癌细胞致瘤性明显减弱，为临床原发性肝癌病人手术前使用该疗法以减少术后肿瘤的复发和播散提供理论依据。In order to study the influence of anti-interleukin-2 receptor α monoclonal(aIL-2R αMAb) and activated killer cells(AK) therapy on tumorigenicity of hepatocarcinoma cells,Syngeneic Balb/c mice were randomly divided into 5 groups.each group contained 8 mice.Then,the therapy by Hanks,IL-2,aIL-2R αMAb and AK were performed.On the 8th day after treatment,the mice were subcutaneously injected with hepatocellular carcinoma H 22 cells.The incidence rate and latent period of subcutaneous tumor were observed,the volume and weight of tumor nodules were measured.The results showed that the incidence rate in the group of IL-2,AK and aIL-2R αMAb was significant higher than that of other groups(P<0.05),latent period of tumor was significantly extented,the growth of subcutaneous tumor was significantly inhibited(P<0.01),the volume and weight of tumor nodules were significantly different compared with the other groups(P<0.01).These results demonstrated that the therapy combined with IL-2,AK and aIL-2R αMAb can reduce the tumorigenicity of hepatocellular carcinoma cells,it will provide theoretic basis for using this method before operation in primary hepatic cancer patients to decrease the recurrence and dissemination of tumor.

关 键 词：杀伤细胞 肝细胞癌 致瘤性 白细胞介素2 受体 

分 类 号：R735.702[医药卫生—肿瘤]